Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, JULY 02, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCEDTHE GRANT OF INDUCEMENT EQUITY AWARDS TO THREE NEWLY HIRED NON-EXECUTIVE EMPLOYEES AS A MATERIAL INDUCEMENT TO COMMENCING THEIR EMPLOYMENT WITH THE COMPANY. THE EMPLOYEES RECEIVED, IN THE AGGREGATE, NON-QUALIFIED STOCK OPTIONS TO PURCHASE 18,025 SHARES OF MONTE ROSA THERAPEUTICS COMMON STOCK, PAR VALUE $0.0001 PER SHARE, WITH AN EXERCISE PRICE PER SHARE EQUAL TO THE CLOSING PRICE OF $24.02 AS REPORTED BY NASDAQ ON JULY 1, THE EFFECTIVE DATE OF THE GRANT OR THE GRANT DATE, WHICH WILL VEST 25% ON THE FIRST ANNIVERSARY OF THE GRANT DATE AND IN 36 EQUAL MONTHLY INSTALLMENTS THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE; AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 3,900 SHARES OF MONTE ROSA THERAPEUTICS COMMON STOCK, WHICH WILL VEST 25% ON EACH OF THE FIRST FOUR ANNIVERSARIES OF THE GRANT DATE, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE, OR COLLECTIVELY, THE AWARDS.

MONTE ROSA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOSTON, JUNE 02, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE),A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCEDTHE GRANT OF INDUCEMENT EQUITY AWARDS TO FOUR NEWLY HIRED NON-EXECUTIVE EMPLOYEES AS A MATERIAL INDUCEMENT TO COMMENCING THEIR EMPLOYMENT WITH THE COMPANY. THE EMPLOYEES RECEIVED, IN THE AGGREGATE, NON-QUALIFIED STOCK OPTIONS TO PURCHASE 20,050 SHARES OF MONTE ROSA THERAPEUTICS COMMON STOCK, PAR VALUE $0.0001 PER SHARE, WITH AN EXERCISE PRICE PER SHARE EQUAL TO THE CLOSING PRICE OF $19.67 AS REPORTED BY NASDAQ ON JUNE 1, THE EFFECTIVE DATE OF THE GRANT OR THE GRANT DATE, WHICH WILL VEST 25% ON THE FIRST ANNIVERSARY OF THE GRANT DATE AND IN 36 EQUAL MONTHLY INSTALLMENTS THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE; AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 4,400 SHARES OF MONTE ROSA THERAPEUTICS COMMON STOCK, WHICH WILL VEST 25% ON EACH OF THE FIRST FOUR ANNIVERSARIES OF THE GRANT DATE, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE, OR COLLECTIVELY, THE AWARDS.

BOSTON, MAY 20, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: TD COWEN 7TH ANNUAL ONCOLOGY INNOVATION SUMMIT (VIRTUAL)  FIRESIDE CHAT, MAY 27, 2026, AT 12:00 P.M. ET JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK  FIRESIDE CHAT, JUNE 4, 2026, AT 11:40 A.M.

MONTE ROSA THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

INTERIM CLINICAL DATA FROM GFORCE-1 TRIAL OF NEK7-DIRECTED MGD MRT-8102 DEMONSTRATED PROFOUND CRP REDUCTIONS IN SUBJECTS WITH ELEVATED CVD RISK; READOUT OF EXPANDED GFORCE-1 TRIAL IN SUBJECTS WITH ELEVATED CVD RISK ANTICIPATED IN H2 2026 COMPANY EXPECTS TO INITIATE MULTIPLE MRT-8102 PHASE 2 STUDIES, INCLUDING IN PATIENTS WITH ELEVATED ATHEROSCLEROTIC RISK IN H2 2026, IN PATIENTS WITH GOUT FLARES IN Q4 2026/Q1 2027, AND IN PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA IN H1 2027 PRESENTED POSITIVE INTERIM PHASE 1/2 CLINICAL DATA OF GSPT1-DIRECTED MGD MRT-2359 IN COMBINATION WITH AN AR INHIBITOR IN MCRPC PATIENTS WITH AR MUTATIONS; INITIATION OF PHASE 2 STUDY EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE IN MCRPC PATIENTS WITH AR MUTATIONS PLANNED FOR Q3 2026 VAV1-DIRECTED MGD MRT-6160 ADVANCING TOWARD ANTICIPATED INITIATION BY NOVARTISOF MULTIPLE PHASE 2 STUDIES IN IMMUNE-MEDIATED DISEASES PRECLINICAL DATA PRESENTED AT AACR HIGHLIGHT A NOVEL CYCLIN E1-DIRECTED MGD WITH SUPERIOR SELECTIVITY AND REDUCED OFF-TARGET ACTIVITY COMPARED TO CDK2 INHIBITORS; IND SUBMISSION ANTICIPATED IN H2 2026 STRONG BALANCE SHEET WITH CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND MARKETABLE SECURITIES OF $671 MILLION, EXPECTED TO SUPPORT OPERATIONS INTO 2029 BOSTON, MAY 07, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY REPORTED BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. WE CONTINUE TO MAKE EXCELLENT PROGRESS ADVANCING MULTIPLE PROGRAMS THROUGH THE CLINIC, WITH ALL THREE OF OUR CLINICAL-STAGE PROGRAMS APPROACHING PHASE 2 TRIAL INITIATIONS, SAID MARKUS WARMUTH, M.D.

MONTE ROSA THERAPEUTICS ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATES

BOSTON, MAY 05, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCEDTHE GRANT OF INDUCEMENT EQUITY AWARDS TO FOUR NEWLY HIRED NON-EXECUTIVE EMPLOYEES AS A MATERIAL INDUCEMENT TO COMMENCING THEIR EMPLOYMENT WITH THE COMPANY. THE EMPLOYEES RECEIVED, IN THE AGGREGATE, NON-QUALIFIED STOCK OPTIONS TO PURCHASE 38,925 SHARES OF MONTE ROSA THERAPEUTICS COMMON STOCK, PAR VALUE $0.0001 PER SHARE, WITH AN EXERCISE PRICE PER SHARE EQUAL TO THE CLOSING PRICE OF $18.80 AS REPORTED BY NASDAQ ON MAY 1, 2026, THE EFFECTIVE DATE OF THE GRANT OR THE GRANT DATE, WHICH WILL VEST 25% ON THE FIRST ANNIVERSARY OF THE GRANT DATE AND IN 36 EQUAL MONTHLY INSTALLMENTS THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE; AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 8,550 SHARES OF MONTE ROSA THERAPEUTICS COMMON STOCK, WHICH WILL VEST 25% ON EACH OF THE FIRST FOUR ANNIVERSARIES OF THE GRANT DATE, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE, OR COLLECTIVELY, THE AWARDS.

CCNE1-DIRECTED MOLECULAR GLUE DEGRADER (MGD) INDUCED DEEP TUMOR REGRESSIONS IN CCNE1-AMPLIFIED IN VIVO MODELS OF OVARIAN, BREAST, AND GASTRIC CANCERS CCNE1-DIRECTED MGD DEMONSTRATED SUPERIOR SELECTIVITY AND REDUCED OFF-TARGET ACTIVITY COMPARED TO CDK2 INHIBITORS ORAL PRESENTATION ON APRIL 21, 2026, AT 2:30 P.M. PT BOSTON, APRIL 20, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC.(NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THE COMPANY WILL PRESENT PRECLINICAL DATA HIGHLIGHTING THE POTENTIAL OF ITS HIGHLY SELECTIVE, FIRST-IN-CLASS CYCLIN E1 (CCNE1)-DIRECTED MGD, MRT-55811, TO TREAT CCNE1-AMPLIFIED SOLID TUMORS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026, BEING HELD APRIL 17-22 IN SAN DIEGO, CA.

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026 ON THE POTENTIAL OF ITS CYCLIN E1 (CCNE1)-DIRECTED MOLECULAR GLUE DEGRADER TO TREAT CCNE1-AMPLIFIED SOLID TUMORS

POSITIVE INTERIM PHASE 1 DATA OF NEK7-DIRECTED MGD MRT-8102 DEMONSTRATED PROFOUND CRP REDUCTIONS IN ELEVATED CVD-RISK SUBJECTS; READOUT OF EXPANDED PART 3 CRP POC TRIAL (NOW CALLED GFORCE-1) ANTICIPATED IN H2 2026 NEWLY ANNOUNCED UNBLINDED SAFETY DATA FROM MRT-8102 SAD/MAD COHORTS CONTINUE TO SUPPORT FAVORABLE SAFETY/TOLERABILITY PROFILE AND WIDE THERAPEUTIC WINDOW COMPANY PLANS TO INITIATE MULTIPLE PHASE 2 STUDIES OF MRT-8102, INCLUDING IN PATIENTS WITH ELEVATED CVD-RISK IN H2 2026, IN PATIENTS WITH GOUT FLARES IN Q4 2026/Q1 2027, AND IN PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA IN H1 2027 PRESENTED POSITIVE INTERIM DATA FROM THE PHASE 1/2 CLINICAL STUDY OF MRT-2359 IN COMBINATION WITH ENZALUTAMIDE SHOWING 100% PSA RESPONSE RATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS WITH AR MUTATIONS PHASE 2 STUDY INITIATION OF MRT-2359 IN COMBINATION WITH APALUTAMIDE IN MCRPC PATIENTS WITH AR MUTATIONS ANTICIPATED IN Q3 2026 VAV1-DIRECTED MGD MRT-6160 ADVANCING TOWARD ANTICIPATED INITIATION BY NOVARTIS OF MULTIPLE PHASE 2 STUDIES IN IMMUNE-MEDIATED DISEASES $345 MILLION UPSIZED FOLLOW-ON FINANCING FURTHER STRENGTHENS BALANCE SHEET, SUPPORTING OPERATIONS INTO 2029 AND THROUGH MULTIPLE ANTICIPATED PHASE 2 STUDY INITIATIONS AND CLINICAL DATA READOUTS BOSTON, MARCH 17, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY REPORTED BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025. MONTE ROSA IS NOW ON THE CUSP OF PHASE 2 TRIAL INITIATIONS FOR THREE CLINICAL-STAGE PROGRAMS, EACH TARGETING EXPANSIVE OPPORTUNITIES.

MONTE ROSA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

MONTE ROSA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO SUPPORT PHASE 2 TRIAL EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE FOR THE TREATMENT

MONTE ROSA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO SUPPORT PHASE 2 TRIAL EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

IN MCRPC PATIENTS WITH ANDROGEN RECEPTOR (AR) MUTATIONS, TREATMENT WITH MRT-2359 IN COMBINATION WITH ENZALUTAMIDE LED TO A 100% PSA RESPONSE RATE (5 OF 5 PATIENTS) AND A 100% DISEASE CONTROL RATE, INCLUDING 2 PATIENTS WITH RECIST PARTIAL RESPONSES AND 3 WITH STABLE DISEASE, ALL SHOWING REDUCTION IN SIZE OF TARGET LESIONS ACROSS ALL 15 EVALUABLE PATIENTS, THE OVERALL RECIST DISEASE CONTROL RATE WAS 67%, AND 10 OF 15 PATIENTS SHOWED TUMOR SIZE REDUCTIONS OF TARGET LESIONS COMBINATION OF MRT-2359 AND ENZALUTAMIDE WAS GENERALLY WELL-TOLERATED WITH PRIMARILY GRADE 1-2 ADVERSE EVENTS (AES); NO TREATMENT DISCONTINUATIONS DUE TO AES COMPANY PLANS TO INITIATE A NEW, SIGNAL-CONFIRMING PHASE 2 STUDY OF MRT-2359 TARGETING AR MUTANT PATIENTS IN Q3 2026 POSTER PRESENTATION ON FEBRUARY 26 AT 11:30 AM PST BOSTON, FEB. 24, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED UPDATED, POSITIVE CLINICAL DATA FROM AN ONGOING PHASE 1/2 CLINICAL STUDY EVALUATING MRT-2359 IN COMBINATION WITH ENZALUTAMIDE IN HEAVILY PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). THE DATA, BEING PRESENTED AT THE 2026 ASCO GU SYMPOSIUM IN SAN FRANCISCO, CA, BUILD ON DATA RELEASED BY THE COMPANY IN DECEMBER 2025.

MONTE ROSA THERAPEUTICS PRESENTS UPDATED CLINICAL DATA FROM PHASE 1/2 STUDY OF MRT-2359 IN COMBINATION WITH ENZALUTAMIDE IN HEAVILY PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS AT ASCO GENITOURINARY CANCERS SYMPOSIUM (ASCO GU)

BOSTON, FEB. 23, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE (BOSTON, MA)  MARKUS WARMUTH, M.D., CHIEF EXECUTIVE OFFICER, TO PRESENT, MARCH 2, 2026, AT 3:10 P.M.

Monte Rosa Therapeutics, Inc.

GLUE

Price

Financial Reports

No items found.

Press Releases

Monte Rosa Therapeutics, Inc.

GLUE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GLUE